2024

1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

   Lung Cancer, Vol. 194

2. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

   Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

3. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

   Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

4. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

   Clinical Drug Investigation, Vol. 44, Núm. 8, pp. 553-576

5. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

   Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789